ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 695

Is a Geriatric Rheumatology Sub-Group Worth Distinguishing? Disease Characteristics  of a Geriatric  Psoriatic Arthritis (Gero PsA) Subgroup Compared with Those of below 45 Years of Age

Euthalia Roussou, Rheumatology, Dr, London, United Kingdom

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Epidemiologic methods and psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster I: Clinical Aspects and Assessments

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:  Adult rheumatologist assess conditions in patients aged 18 and above. There is no distinction to those of the frail age of 65 and above who could belong to a geriatric rheumatology group. Aims:To assess whether there are differences between psoriatic arthritis (PsA)  patients aged above 65 years (y). To compare demographic, (gender ratio,  ethnicity, social habits) disease characteristics, activity and function( disease  duration, delay in diagnosis, ESR, CRP, Night pain, sleep disturbance, BASDAI, BASFI) and treatment (Tx)options as wells as treatment effect, and well being over past week (wbpw) and over past 6 months (wb6m) of those above 65y with those aged below 45y.

Methods: From total  719 patients (pts) with Spondyloarthritis  (SpA) registered in the London Registry of SpA (LoRoS) which has been developed aiming to assess differences in SpAs between ethnic groups over time, (ethics approval REC 07/H0701/74) 247 pts had confirmed PsA  by CASPAR.  From the total of 247 pts, 45 pts had their baseline characteristics recorded at age 65y (or above) and formed  the Gero PsA group (gPsA) which has been analysed and compared with those patients who entered in the registry at age below45y (b45) (n=73).  The remaining patients belonging in the intermediate age group of between 45 to 64 (intag)(n=124) has been analysed where there were discrepancies.

Results: Table shows the disease characteristics of the geroPsA group compared with those of below 45, ssd and CI.   The statistically significant difference(ssd) between the ethnic groups studied  in our cohort compatible with national ethnic migration reports.  Smoking reported by more b45 but did not reach ssd. There was no difference in the Tx between the gPsA and the b45 except a borderline difference in the Tx with Sulphasalazine (SSZ)in that more pts b45 were on SSZ [P=0.08 (CI= -0.21 to 0.18)] while more gPsA patients had joint surgery (p=0.01; CI=0.065 to 0.45).

Conclusion: PsA patients above the age of 65y have differences compared with the younger age group and can form a distinct geriatric PsA group. Differences identified in our cohort were related to ethnicity, social habits, inflammatory markers, function and treatment options and effect.

Items

Gero PsA(n=45)

mean (sd)

Below45y (n=73)

mean (sd)

Pvalues CI (lower to upper
Gender 16:29(1:2) 24:49(1:2) n/a
Ethnic group

Caucasian=38/45 (84.4%)

Asian =3/45 (6.6%)

African =4/45 (8.8)

caucasian=38/73 (52%)

Asian=29/73 (42.4%)

African=3/73 (4%)

mixed race 1/73

p=0.03

p=0.04

p=0.7

Alcohol intake 57.7% 46.5% p=0.02 0.0028 to 0.44
Delay in diagnosis (years) 9.4 (15.3)  3.3 (3.9) p=0.05 0.002 to 12.2
Disease duration 11.9 (15.5) 4.6 (4.2) p=0.02 1.1 to 13.4
ESR 23.7 (19) 19.1(22) p=0.2 =3.1 to 12.3
CRP 7.6 (6.8) 7.6(6.6) p=0.9 -3.3 to 3.2
Night Pain 3.9(3.3) 5.4(3) p=0.06 -3.2 to 0.09
Sleep disturbance 3.9 (3.3) 5.3(3.2) p=0.1 -3.4 to 0.48
BASDAI score 5.2(2.3) 6.06(2.2) p=9.1 -2.07 to 0.3
BASFI score 5.63 (2.7) 4.09(2.6) p=0.02 0.23 to 2.85
Treatment effect (VAS) perceived 5.1(2.7) 4.04(2.04) p=0.08 -0.17 to 2.3
Well being past week 4.58(2.8) 5.46(2.7) p=0.1 -2.17 to 0.41

Disclosure: E. Roussou, None;

To cite this abstract in AMA style:

Roussou E. Is a Geriatric Rheumatology Sub-Group Worth Distinguishing? Disease Characteristics  of a Geriatric  Psoriatic Arthritis (Gero PsA) Subgroup Compared with Those of below 45 Years of Age [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/is-a-geriatric-rheumatology-sub-group-worth-distinguishing-disease-characteristics-of-a-geriatric-psoriatic-arthritis-gero-psa-subgroup-compared-with-those-of-below-45-years-of-age/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/is-a-geriatric-rheumatology-sub-group-worth-distinguishing-disease-characteristics-of-a-geriatric-psoriatic-arthritis-gero-psa-subgroup-compared-with-those-of-below-45-years-of-age/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology